News

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announces today that it has agreed on a EURO 32 million investment to complete the Oxabact® development program for treatment of Primary hyperoxaluria. The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders Kurma Partners, France, Idinvest Partners, France, Stiftelsen Industrifonden, Sweden, and Brohuvudet, Sweden. This announcement bolsters OxThera’s position as a leader in developing therapies for Primary hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.

Alligator är ett forskningsbaserat bioteknikföretag som utvecklar innovativa immunaktiverande antikroppsläkemedel för tumörriktad immunterapi. Bolaget har sitt säte i Lund och hade 35 anställda per den 30 september 2016. Alligator är främst verksamt i de tidiga faserna av läkemedelsutvecklingen, från idéstadium till och med kliniska fas IIa-studier och Bolagets projektportfölj består främst av produktkandidaterna ADC-1013, ATOR-1015 och ATOR-1016. I augusti 2015 utlicensierades ADC-1013 till Janssen Biotech, Inc., ett Janssen-läkemedelsföretag inom Johnson & Johnson-koncernen, för vidareutveckling och kommersialisering. Bolagets aktier är noterade på Nasdaq Stockholm under kortnamnet ”ATORX”. För mer information, se http://www.alligatorbioscience.se.

För mer information, vänligen kontakta:
Per Norlén, VD
Telefon: +46 46 286 42 80
E-post: pen [at] alligatorbioscience [dot] com

Rein Piir, VP Investor Relations
Telefon: +46 708 537292
E-post: rpr [at] alligatorbioscience [dot] com

Informationen i pressmeddelandet är sådan som Alligator Bioscience AB är skyldigt att offentliggöra enligt lagen om handel med finansiella instrument.

Sunstone Life Science Fund III portfolio company Rigontec, the leader in RIG-I targeting RNA therapeutics, has announced that Dr. Jörg Vollmer has joined the Company as Chief Scientific Officer. Dr. Vollmer brings to Rigontec more than 17 years of drug discovery and development experience including leadership roles at Nexigen GmbH, Pfizer and Coley Pharmaceutical. Dr. Vollmer will be responsible for leading Rigontec’s R&D efforts and advancing the Company’s RIG-I-based platform focused on discovering and developing treatments for oncological and infectious diseases. He will report to Dr. Christian Schetter, CEO of Rigontec, and will be based in Munich.

F2G Ltd, the UK-based antifungal drug discovery and development company, has announced the publication of the initial F901318 data in the prestigious scientific journal Proceedings of the National Academy of Sciences (PNAS), of their work in elucidating the mechanism of action of its novel orotomide antifungal – lead candidate F901318. The study entitled “F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase” can be found here: http://www.pnas.org/content/early/2016/10/24/1608304113.abstract.

Anders Hinsby, CEO of Orphazyme ApS, says: “The whole team at Orphazyme has been working tirelessly to bring our technology and scientific advancements from the laboratory into the clinic. With Thomas Blaettler now on board, we will be well equipped to design and implement long-term clinical strategies, fulfilling our aim to improve the lives of those suffering with rare, and often fatal, diseases.”